Table 3.
Tolerability and systemic adverse effects experienced by Moderna vaccine recipients after second dose35.
| Individuals 18 to 64 |
Individuals 65 and older |
|||
| |
Mild |
Severe (resulting in debilitating symptoms) |
Mild |
Severe (resulting in debilitating symptoms) |
| Tolerability (Local and immediate reactions) | ||||
| Injection Site Pain | 90.1% | 4.6% | 83.4% | 2.7% |
| Erythema | 9.0% | 2.0% | 7.4% | 2.1% |
| Swelling | 12.6% | 1.7% | 10.8% | 1.9% |
| Systemic Reactions | ||||
| Headache | 62.8% | 5.0% | 46.4% | 3.0% |
| Fatigue | 67.6% | 10.6% | 58.4% | 6.9% |
| Myalgia | 61.3% | 10.0% | 46.9% | 5.6% |
| Nausea | 21.3% | <0.1% | 11.8% | 0.3% |
| Fever | 17.4% | 1.6% | 10.2% | 0.5% |